Ex-Purdue Pharma chief Mark Timney, named in dozens of opioid lawsuits, nabs another biotech CEO gig

Facing hundreds of lawsuits over its role in fueling the US opioid epidemic, Purdue Pharma is in the midst of full-scale teardown — but that doesn’t mean its former leaders aren’t making off well. Coming off a stint driving RNAi therapy inclisiran to a buyout, former Purdue CEO Mark Timney has found a new home at the helm of a small biotech.